Michael Cherny
Stock Analyst at Leerink Partners
(4.35)
# 324
Out of 5,170 analysts
120
Total ratings
59.09%
Success rate
14.46%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HIMS Hims & Hers Health | Maintains: Market Perform | $18 → $25 | $24.16 | +3.48% | 12 | Mar 16, 2026 | |
| TDOC Teladoc Health | Maintains: Market Perform | $8.5 → $5.5 | $5.52 | -0.36% | 2 | Feb 26, 2026 | |
| HSIC Henry Schein | Maintains: Market Perform | $75 → $87 | $72.68 | +19.70% | 3 | Feb 24, 2026 | |
| ACH Accendra Health | Maintains: Market Perform | $3 → $2.75 | $2.03 | +35.47% | 1 | Feb 20, 2026 | |
| XRAY DENTSPLY SIRONA | Upgrades: Buy | $13 → $17 | $11.26 | +50.98% | 9 | Feb 19, 2026 | |
| MEDP Medpace Holdings | Maintains: Market Perform | $575 → $485 | $460.92 | +5.22% | 2 | Feb 11, 2026 | |
| CVS CVS Health | Maintains: Buy | $100 → $95 | $71.86 | +32.20% | 12 | Jan 27, 2026 | |
| MDLN Medline | Initiates: Outperform | $48 | $43.59 | +10.12% | 1 | Jan 12, 2026 | |
| CERT Certara | Upgrades: Outperform | $13 | $6.38 | +103.76% | 2 | Jan 6, 2026 | |
| DGX Quest Diagnostics | Maintains: Outperform | $203 → $210 | $194.16 | +8.16% | 3 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $785 → $850 | $898.95 | -5.45% | 15 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $188 → $186 | $210.92 | -11.81% | 13 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $28 | $18.18 | +54.02% | 11 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $15 → $3 | $1.17 | +156.41% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $23 | $25.26 | -8.95% | 11 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $90 | $24.80 | +262.90% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $235 → $280 | $176.25 | +58.87% | 3 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $166.47 | +48.98% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $98.05 | +160.07% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $331.74 | -17.10% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $264.09 | -1.55% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $2.15 | +272.09% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $1.48 | +3,447.30% | 2 | Jan 5, 2022 |
Hims & Hers Health
Mar 16, 2026
Maintains: Market Perform
Price Target: $18 → $25
Current: $24.16
Upside: +3.48%
Teladoc Health
Feb 26, 2026
Maintains: Market Perform
Price Target: $8.5 → $5.5
Current: $5.52
Upside: -0.36%
Henry Schein
Feb 24, 2026
Maintains: Market Perform
Price Target: $75 → $87
Current: $72.68
Upside: +19.70%
Accendra Health
Feb 20, 2026
Maintains: Market Perform
Price Target: $3 → $2.75
Current: $2.03
Upside: +35.47%
DENTSPLY SIRONA
Feb 19, 2026
Upgrades: Buy
Price Target: $13 → $17
Current: $11.26
Upside: +50.98%
Medpace Holdings
Feb 11, 2026
Maintains: Market Perform
Price Target: $575 → $485
Current: $460.92
Upside: +5.22%
CVS Health
Jan 27, 2026
Maintains: Buy
Price Target: $100 → $95
Current: $71.86
Upside: +32.20%
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $48
Current: $43.59
Upside: +10.12%
Certara
Jan 6, 2026
Upgrades: Outperform
Price Target: $13
Current: $6.38
Upside: +103.76%
Quest Diagnostics
Oct 21, 2025
Maintains: Outperform
Price Target: $203 → $210
Current: $194.16
Upside: +8.16%
Sep 24, 2025
Maintains: Outperform
Price Target: $785 → $850
Current: $898.95
Upside: -5.45%
Aug 12, 2025
Maintains: Outperform
Price Target: $188 → $186
Current: $210.92
Upside: -11.81%
Jul 8, 2025
Upgrades: Outperform
Price Target: $28
Current: $18.18
Upside: +54.02%
May 28, 2025
Downgrades: Market Perform
Price Target: $15 → $3
Current: $1.17
Upside: +156.41%
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $25.26
Upside: -8.95%
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $24.80
Upside: +262.90%
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $176.25
Upside: +58.87%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $166.47
Upside: +48.98%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $98.05
Upside: +160.07%
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $331.74
Upside: -17.10%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $264.09
Upside: -1.55%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $2.15
Upside: +272.09%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $1.48
Upside: +3,447.30%